Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NYX-2925 in subjects with fibromyalgia.
This 13- to 16-week study will include a 1- to 4-week Screening Period followed by a 12-week double-blind, randomized, placebo-controlled Treatment Period.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85012
- Aptinyx Clinical Site
-
-
California
-
Culver City, California, United States, 90230
- Aptinyx Clinical Site
-
Fresno, California, United States, 93710
- Aptinyx Clinical Site
-
Orange, California, United States, 92868
- Aptinyx Clinical Site
-
Redlands, California, United States, 92374
- Aptinyx Clinical Site
-
Temecula, California, United States, 92591
- Aptinyx Clinical Site
-
Torrance, California, United States, 90502
- Aptinyx Clinical Site
-
-
Florida
-
Fernandina Beach, Florida, United States, 32034
- Aptinyx Clinical Site
-
Jacksonville, Florida, United States, 32256
- Aptinyx Clinical Site
-
Jacksonville, Florida, United States, 32224
- Aptinyx Clinical Site
-
Lady Lake, Florida, United States, 32159
- Aptinyx Clinical Site
-
Miami, Florida, United States, 33165
- Aptinyx Clinical Site
-
Orlando, Florida, United States, 32801
- Aptinyx Clinical Site
-
Palmetto Bay, Florida, United States, 33157
- Aptinyx Clinical Site
-
Winter Park, Florida, United States, 32789
- Aptinyx Clinical Site
-
-
Georgia
-
Alpharetta, Georgia, United States, 30022
- Aptinyx Clinical Site
-
-
Illinois
-
Chicago, Illinois, United States, 60607
- Aptinyx Clinical Site
-
Flossmoor, Illinois, United States, 60422
- Aptinyx Clinical Site
-
Gurnee, Illinois, United States, 60031
- Aptinyx Clinical Site
-
Skokie, Illinois, United States, 60076
- Aptinyx Clinical Site
-
-
Indiana
-
Evansville, Indiana, United States, 47714
- Aptinyx Clinical Site
-
-
Iowa
-
West Des Moines, Iowa, United States, 50265
- Aptinyx Clinical Site
-
-
Kansas
-
Newton, Kansas, United States, 67114
- Aptinyx Clinical Site
-
Prairie Village, Kansas, United States, 66208
- Aptinyx Clinical Site
-
Wichita, Kansas, United States, 67205
- Aptinyx Clinical Site
-
-
Massachusetts
-
Roslindale, Massachusetts, United States, 02131
- Aptinyx Clinical Site
-
-
Missouri
-
Hazelwood, Missouri, United States, 63042
- Aptinyx Clinical Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Aptinyx Clinical Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89102
- Aptinyx Clinical Site
-
-
New York
-
Brooklyn, New York, United States, 11235
- Aptinyx Clinical Site
-
New York, New York, United States, 10036
- Aptinyx Clinical Site
-
New York, New York, United States, 10017
- Aptinyx Clinical Site
-
Staten Island, New York, United States, 10312
- Aptinyx Clinical Site
-
Williamsville, New York, United States, 14221
- Aptinyx Clinical Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Aptinyx Clinical Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73106
- Aptinyx Clinical Site
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Aptinyx Clinical Site
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Aptinyx Clinical Site
-
-
Texas
-
Austin, Texas, United States, 78737
- Aptinyx Clinical Site
-
Houston, Texas, United States, 77077
- Aptinyx Clinical Site
-
-
Virginia
-
Danville, Virginia, United States, 24541
- Aptinyx Clinical Site
-
-
Washington
-
Bellevue, Washington, United States, 98007
- Aptinyx Clinical Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Informed consent
- Subject has a history of fibromyalgia that was diagnosed >1 year prior to screening and reports at least moderate pain over the last week
- Stable protocol allowed medication and other therapies during the study
- Agrees to use highly effective birth control during the study
- Has not participated in an interventional study for at least 30 days and agrees not to participate in another interventional study during the study
Exclusion Criteria:
- Pain due to other conditions or diseases that would complicate participation in the study or pain reporting
- Current or historical serious medical conditions
- Prior participation in NYX-2925 clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Placebo administered orally.
|
Placebo administered orally
|
|
Experimental: NYX-2925 50 mg
NYX-2925 50 mg administered orally.
|
NYX-2925 administered orally
|
|
Experimental: NYX-2925 100 mg
NYX-2925 100 mg administered orally.
|
NYX-2925 administered orally
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the Mean Numerical Rating Scale (NRS) Score
Time Frame: Week 12
|
Change from baseline to Week 12 in the weekly mean of the daily Numerical Rating Scale (NRS) score assessing average pain intensity in the past 24 hours, scores range from 0-10, with higher scores indicating worse pain (0 being no pain and 10 being the worst possible pain)
|
Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Subjects "Much Improved" or "Very Much Improved" on the Patient Global Impression of Change (PGI-C) at Week 12
Time Frame: Week 12
|
Number of subjects "much improved" or "very much improved" on the Patient Global Impression of Change (PGI-C) at Week 12
|
Week 12
|
|
Daily Sleep Interference (DSIS) Score
Time Frame: Week 12
|
Change from baseline in the weekly mean of the Daily Sleep Interference Scale (DSIS) scores at Week 12; Response options range from 0 (Did not interfere with sleep) to 10 (Completely interfered with sleep, unable to sleep due to pain), with higher scores indicating greater interference with sleep.
|
Week 12
|
|
Number of Subjects Achieving ≥30% Pain Reduction
Time Frame: Week 12
|
Number of subjects achieving ≥30% reduction from baseline in the weekly mean NRS average pain intensity at Week 12; NRS Scores range from 0-10, with higher scores indicating worse pain (0 being no pain and 10 being the worst possible pain).
|
Week 12
|
|
Number of Subjects Achieving ≥50% Pain Reduction
Time Frame: Week 12
|
Number of subjects achieving ≥50% reduction from baseline in the weekly mean NRS average pain intensity at Week 12; NRS scores range from 0-10, with higher scores indicating worse pain (0 being no pain and 10 being the worst possible pain)
|
Week 12
|
|
Fibromyalgia Impact Questionnaire-Revised (FIQR) Score
Time Frame: Week 12
|
Change from baseline to Week 12 in the Fibromyalgia Impact Questionnaire - Revised (FIQR) score; FIQR scores range from 0-100, with higher scores indicating greater impact of fibromyalgia
|
Week 12
|
|
Patient Reported Outcomes Measurement Information System - Fibromyalgia (PROMIS-FM) Sleep Disturbance Score
Time Frame: Week 12
|
Change from baseline to Week 12 in the PROMIS-FM sleep disturbance score, scores range from 0-40, with higher scores indicating greater sleep disturbance.
|
Week 12
|
|
Patient Reported Outcomes Measurement Information System - Fibromyalgia (PROMIS-FM) Fatigue Profile Score
Time Frame: Week 12
|
Change from baseline to Week 12 in the PROMIS-FM fatigue profile score, scores range from 0-80, with higher scores indicating greater impact of fatigue
|
Week 12
|
|
Patient Reported Outcomes Measurement Information System - Fibromyalgia (PROMIS-FM) Physical Function Score
Time Frame: Week 12
|
Change from baseline to Week 12 in the PROMIS-FM physical function score, scores range from 0-60, with higher scores indicating greater difficulty with physical function.
|
Week 12
|
|
Use of Rescue Medication
Time Frame: Week 12
|
The number of subjects using rescue medication.
|
Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NYX-2925-2005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.